Zydus receives EIR with VAI from USFDA for its Moraiya formulations manufacturing facility

7 Nov 2022 , 10:05 AM

Zydus Lifesciences Ltd has announced the receipt of an Establishment Inspection Report (EIR) from the United States Food and Drug Administration (USFDA) for its formulations manufacturing facility in Moraiya, near Ahmedabad, India.

As per the filing, the USFDA has determined that the inspection classification of the facility is Voluntary Action Indicated (VAI).

The USFDA had inspected the facility from July 26 to August 05, 2022 which concluded with four observations. The USFDA has indicated that the inspection is closed.

On Monday, at around 10:06 AM, Zydus Lifesciences Ltd is currently trading at Rs444 per share up by Rs4.2 or 0.95% from its previous closing of Rs439.80 per share on the BSE.

For feedback and suggestions, write to us at [e-mail]